Table 2.
Demographics and clinical data of studied ADNIGO/2 subjects at baseline.
| CN (n = 177) |
SMC (n = 98) |
EMC (n = 284) |
LMCI (n = 148) |
AD (n = 133) |
p-value | |
|---|---|---|---|---|---|---|
| Age (years) | 73.46 (6.29) | 72.18 (5.63) | 71.12 (7.51) | 72.12 (7.64) | 74.21 (8.33) | <0.001 |
| Sex, Female % (n) | 53% (94) | 57% (56) | 46% (130) | 48% (71) | 41% (55) | 0.09 |
| APOE ε4, % (n) | 28% (50) | 33% (32) | 43% (121) | 57% (84) | 65% (87) | <0.001 |
| MMSE, M (SD) | 29.03 (1.27) | 29.00 (1.20) | 28.32 (1.60) | 27.64 (1.79) | 23.06 (2.06) | <0.001 |
| ADAS-Cog13, M (SD) | 9.05 (4.48) | 8.78 (4.12) | 12.64 (5.40) | 18.80 (7.31) | 31.10 (8.67) | <0.001 |
Abbreviations: AD-Alzheimer’s disease; ADAS-Cog13: Alzheimer’s Disease Assessment Scale-Cognitive subscale; CN-cognitively normal; EMCI: early mild cognitive impairment; MMSE-Mini-Mental State Exam; LMCI-late MCI; SMC- subjective memory complaints.